HDAX Therapeutics logo

About us

HDAX Therapeutics is pioneering next-gen small molecule therapeutics to transform patient outcomes in neuropathies, cardiometabolic diseases and beyond. By leveraging our unique molecular recognition technology, HDAX has engineered a novel 2-site binding mechanism to target the validated and attractive disease driver protein HDAC6, which overcomes critical shortcomings of current molecules such as weak binding, poor BBB penetration, off-target toxicities, and suboptimal PK profiles.

HDAX has a pipeline of central-acting molecules for neuromuscular indications (Chemotherapy-induced peripheral neuropathy – animal efficacy completed with full disease reversal and cognitive benefits observed, Charcot-Marie-Tooth) and peripheral-restricted molecules for cardiometabolic diseases (Heart failure with preserved ejection fraction, obesity).

Program engagement

HDAX Therapeutics

Leadership

Nabanita Nawar

Co-founder and CEO

Pimyupa Manaswiyoungkul

Co-founder and COO

Status

Intellectual Property

Fundraising

Sector

Subsector

Synapse Life Science Pitch Competition applications open. Apply by November 10, 2024

Applications for the 2025 Synapse Competition are open!

The Synapse Life Science Competition combines the ideas and research of life science innovators with the intellect and strategy of students. Finalists receive training, mentorship, a $2,000 grant and a chance to pitch and compete for BIG cash prizes!

Applications close on November 10, 2024.